ELOCTATE
Biological
BIOVERATIV THERAPEUTICS INC.
Total Payments
$2.8M
Transactions
1,948
Doctors
234
Companies
7
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $62,513 | 49 | 31 |
| 2023 | $8,216 | 17 | 14 |
| 2022 | $167,062 | 157 | 55 |
| 2021 | $301,037 | 192 | 46 |
| 2020 | $507,360 | 273 | 49 |
| 2019 | $738,339 | 639 | 98 |
| 2018 | $967,946 | 558 | 50 |
| 2017 | $51,358 | 63 | 5 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.1M | 1,185 | 73.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $544,134 | 240 | 19.4% |
| Travel and Lodging | $103,942 | 177 | 3.7% |
| Consulting Fee | $73,222 | 27 | 2.6% |
| Food and Beverage | $16,498 | 276 | 0.6% |
| Space rental or facility fees (teaching hospital only) | $1,250 | 3 | 0.0% |
| Education | $586.74 | 40 | 0.0% |
Payments by Type
Research
$2.1M
1,185 transactions
General
$739,632
763 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adult | BIOVERATIV THERAPEUTICS INC. | $387,459 | 6 |
| An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A | BIOVERATIV THERAPEUTICS INC. | $322,084 | 10 |
| An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia A | BIOVERATIV THERAPEUTICS INC. | $237,852 | 0 |
| Implications of Fc receptor-targeting in the down-regulation of inflammatory and angiogenic responses after hemarthrosis that contribute to the development of hemophilic arthropathy | BIOVERATIV THERAPEUTICS INC. | $224,346 | 0 |
| Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment | BIOVERATIV THERAPEUTICS INC. | $203,662 | 9 |
| Implications of Fc receptor-targeting in the down-regulation of inflammatory and angiogenic responses after hemarthrosis that contribute to the development of hemophilic arthropathy | GENZYME CORPORATION | $174,346 | 0 |
| A Non-controlled, Open-Label, Multicenter, Study of Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Subjects With Inhibitors Undergoing the First ITI Treatment | BIOVERATIV THERAPEUTICS INC. | $117,257 | 0 |
| A NON CONTROLLED, OPEN-LABEL, MULTICENTER, EXPLORATORY PHASE 2 STUDY OF EFFICACY OF RFVIIIFC FOR ITI IN SEVERE HEMOPHILIA A PATIENTS WITH INHIBITORS WHO HAVE FAILED PREVIOUS ITI THERAPIES | SWEDISH ORPHAN BIOVITRUM AB | $96,837 | 0 |
| An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) in the Prevention and Treatment of Bleeding in Previously | BIOVERATIV THERAPEUTICS INC. | $70,579 | 0 |
| ISS - RARE BLOOD DISORDERS | GENZYME CORPORATION | $50,000 | 0 |
| An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A | Biogen, Inc. | $35,903 | 0 |
| SOBI.ELOCTA-003 | SWEDISH ORPHAN BIOVITRUM AB | $26,927 | 0 |
| A Non-controlled, Open-Label, Multicenter, Study of Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Subjects With Inhibitors Undergoing the First ITI Treatment | SANOFI US SERVICES INC. | $20,634 | 0 |
| Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A | BIOVERATIV THERAPEUTICS INC. | $19,511 | 3 |
| An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A | SANOFI US SERVICES INC. | $14,235 | 0 |
| Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale | Biogen, Inc. | $11,707 | 0 |
| A retrospective chart review to assess clinical characteristics of women and girls with factor VIII and IX deficiency | BIOVERATIV THERAPEUTICS INC. | $9,830 | 3 |
| Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale | BIOVERATIV THERAPEUTICS INC. | $7,118 | 3 |
| Retrospective chart review of hemophilia A patients with inhibitors treated with rFVIIIFc for ITI | BIOVERATIV THERAPEUTICS INC. | $5,186 | 8 |
| An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia A | GENZYME CORPORATION | $4,500 | 2 |
Top Doctors Receiving Payments for ELOCTATE
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Salt Lake City, UT | $1.5M | 759 |
| , M.D | Pediatric Hematology-Oncology | Lansing, MI | $125,313 | 96 |
| , M.D | Hematology | Los Angeles, CA | $111,766 | 80 |
| , MD | Pediatric Hematology-Oncology | Miami, FL | $99,231 | 72 |
| , MD | Hematology & Oncology | Seattle, WA | $76,497 | 53 |
| , MD | Pediatric Hematology-Oncology | Indianapolis, IN | $71,024 | 57 |
| , M.D | Pediatric Hematology-Oncology | Los Angeles, CA | $67,918 | 59 |
| , MD | Hematology & Oncology | Milwaukee, WI | $67,156 | 31 |
| , M.D | Internal Medicine | Memphis, TN | $56,013 | 45 |
| , M.D., PHD | Hematology & Oncology | Sacramento, CA | $49,203 | 41 |
| , M.D | Pediatrics | Miami, FL | $44,858 | 41 |
| , MD | Pediatric Hematology-Oncology | Atlanta, GA | $43,367 | 6 |
| , MD | Pediatric Hematology-Oncology | Nashville, TN | $34,390 | 25 |
| , M.D | Pediatric Hematology-Oncology | Milwaukee, WI | $32,588 | 31 |
| , M.D | Pediatric Hematology-Oncology | Madera, CA | $30,274 | 25 |
| , MD | Specialist | Pittsburgh, PA | $29,164 | 22 |
| , MD | Hematology | Columbus, OH | $28,007 | 35 |
| , MD | Pediatric Hematology-Oncology | Aurora, CO | $24,751 | 22 |
| , MD | Pediatric Hematology-Oncology | Miami, FL | $23,308 | 20 |
| , MD | Pediatrics | Washington, DC | $22,325 | 16 |
| , MD | Pediatric Hematology-Oncology | Orange, CA | $16,062 | 18 |
| , MD | Internal Medicine | Minneapolis, MN | $15,180 | 9 |
| , MD | Pediatrics | Detroit, MI | $14,139 | 5 |
| , M.D | Pediatric Hematology-Oncology | Las Vegas, NV | $12,359 | 11 |
| , MD | Hematology & Oncology | San Diego, CA | $11,417 | 6 |
Ad
Manufacturing Companies
- BIOVERATIV THERAPEUTICS INC. $2.0M
- GENZYME CORPORATION $521,688
- SWEDISH ORPHAN BIOVITRUM AB $190,966
- Biogen, Inc. $51,358
- SANOFI-AVENTIS U.S. LLC $50,526
- SANOFI US SERVICES INC. $34,869
- Swedish Orphan Biovitrum AB $4,200
Product Information
- Type Biological
- Total Payments $2.8M
- Total Doctors 234
- Transactions 1,948
About ELOCTATE
ELOCTATE is a biological associated with $2.8M in payments to 234 healthcare providers, recorded across 1,948 transactions in the CMS Open Payments database. The primary manufacturer is BIOVERATIV THERAPEUTICS INC..
Payment data is available from 2017 to 2024. In 2024, $62,513 was paid across 49 transactions to 31 doctors.
The most common payment nature for ELOCTATE is "Unspecified" ($2.1M, 73.6% of total).
ELOCTATE is associated with 20 research studies, including "A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adult" ($387,459).